Trial Profile
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Niraparib (Primary) ; Oregovomab (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms FLORA-4
- Sponsors OncoQuest
- 11 Jan 2024 Planned End Date changed from 30 Oct 2024 to 30 Dec 2024.
- 11 Jan 2024 Planned primary completion date changed from 30 Jan 2024 to 30 Mar 2024.
- 28 Aug 2023 Planned End Date changed from 30 May 2024 to 30 Oct 2024.